The Journal of the Society of Stroke on Korean Medicine (대한중풍순환신경학회지)

The Society of Stroke on Korean Medicine (대한중풍순환신경학회)
권호 표지

A Case of Pleural Effusion in a Patient with Heart Failure with Preserved Ejection Fraction Improved by A Combined Korean-Western Medicine Approach

좌심실 수축 기능 보전 심부전증으로 인한 흉수에 대한 한양방 복합치료 치험 1례

  • Ha, Won Jung (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University) ;
  • Seo, Yuna (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University) ;
  • Lee, Young seon (Dept. of Clinical Korean Medicine, Graduate school, Kyung-Hee University) ;
  • Cho, Ki-Ho (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit) ;
  • Mun, Sang-Kwan (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit) ;
  • Jung, Woo-Sang (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit) ;
  • Kwon, Seungwon (Dept. of Cardiology and Neurology, College of Korean medicine, Kyung-Hee Universit)
  • 하원정 (경희대학교 대학원 임상한의학과) ;
  • 서유나 (경희대학교 대학원 임상한의학과) ;
  • 이영선 (경희대학교 대학원 임상한의학과) ;
  • 조기호 (경희대학교 한의과대학 순환신경내과학교실) ;
  • 문상관 (경희대학교 한의과대학 순환신경내과학교실) ;
  • 정우상 (경희대학교 한의과대학 순환신경내과학교실) ;
  • 권승원 (경희대학교 한의과대학 순환신경내과학교실)
  • Published : 2021.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

■ Background Heart Failure with Preserved Ejection Fraction(HFpEF) is a heart failure that appears to have normal contraction function. In the case of HFpEF, no pharmacological therapy has been found to improve clinical prognosis, so it should be approached as an symptomatic treatment, therefore alternatives are needed due to concerns over adverse effects such as electrolyte imbalance caused by medication. ■ Case report A 81 year old female patient with Heart Failure with Preserved Ejection Fraction(HFpEF) patient complained dyspnea. Herbal prescription Mokbanggi-tang and Oryeongsan was administered on 6th day and 8th day respectively since the symptoms started. The NYHA Classification and Chest X-ray had been evaluated during the treatment period. Until the 7th day, the patient was classified as Class II, and when discharged from the hospital on the 28th day, it gradually improved and was classified as Class II. Chest X-Ray took on 2nd day showed pleural effusion and it was aggravated until 13th day. Follow up Chest X-Ray showed improving state of pleural effusion from 20th day and gradually got better. Mokbanggi-tang treatment continued for 52 days and stopped on 58th day. After Mokbanggi-tang treatment ended, only Oryeongsan treatment was maintained. ■ Conclusion The present case report suggests that Korean-Western medicine approach with Mokbangki-tang and Oryeongsan might be effective to pleural effusion and heart failure symptoms such as poor physical activity shown in a NYHA Classification. This shows that Mokbanggi-tang and Oryeongsan can be a therapeutic option as a treatment for patient with Heart Failure with Preserved Ejection Fraction(HFpEF).

Keywords

References

  1. Kim YD. Heart Failure with Preserved Ejection Fraction: Current Diagnostic and Therapeutic Approach. 2016;90(1):20-25.
  2. Park JJ, Choi DJ. Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. Korean J Med. 2015;88(2):127-134. https://doi.org/10.3904/kjm.2015.88.2.127
  3. Bennett JA, Riegel B, Bittner V, Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262-70. https://doi.org/10.1067/mhl.2002.124554
  4. Na SJ, Bae SH. Optimal Management of Heart Failure with Preserve Ejection Fraction. Korean J Med. 2015;88(2):135-141. https://doi.org/10.3904/kjm.2015.88.2.135
  5. Lee JH, Koo BK. Pleural Effusion in Cardiovascular Disease. Korean J Med. 2011;81(2):161-166.
  6. Jeong MJ, Kang KW, Kang JY et al. An Overview of the Applicability of Oryung-san as an Antihypertensive Agent. J. Int. Korean Med. 2017;38(4):443-454. https://doi.org/10.22246/jikm.2017.38.4.443
  7. 조기호, 권승원. 경계 너머의 한방처방. 경기:물고기숲. 2012:201.
  8. 張仲景. 元.鄧珍本金匱要略2-4b~2-5a. 燎原書店復刻版. 1988. 86-87.
  9. EZAKI H, INOKUCHI T, TANIWAKI M, YAMAMOTO H, DOI H, MIYAKE T, SAKURADA M. Efficacy of Mokuboito in Patients with Severe Intractable Heart Failure. Kampo Medicine. 2016;67(2):169-177. https://doi.org/10.3937/kampomed.67.169
  10. Otsuka,K. Kampo-lgaku(漢方医学), Osaka:Sougen-sha. 1973:150.
  11. 조한진, 이경섭. 목방기탕(木防己湯)이 강심이뇨 및 심장박동에 미치는 영향. 대한한의학회지. 1984;5(1): 28-34.
  12. Seiichiro Nishida, Hiroyasu Satoh. Vascular Pharmacology of Mokuboito (Mu-Fang-YiTang) and Its Constituents on the Smooth Muscle and the Endothelium in Rat Aorta. eCAM. 2007;4(3):335-341.
  13. Nishida S, Satoh H. Vascular pharmacology of mokuboito(mu-fang-yi-tang) and its constituents on the smooth muscle and the endothelium in rat aorta. Evid Based Complement Alternat Med. 2007;4:335-341. https://doi.org/10.1093/ecam/nel097
  14. Satoh H, Sperelakis N. Review of some actions of taurine on ion channels of cardiac muscle cells and others. Gen Pharmacol. 1998;30:451-463. https://doi.org/10.1016/S0306-3623(97)00309-1
  15. 한의과대학 방제학교수 공편저. 방제학. 서울:영림사; 2003:504-6.
  16. Ito Y. Pathophysiology of the Goreisan show lowering of osmolality set point. Japanese Journal of Oriental Medicine. 1978;28:91-9.
  17. Isohama Y. Modulation of aquaporin water channel function by Kampo medicines. Kampo and the newest therapy. 2008;17:27-35.
  18. Kurita T, Nakamura K, Tabuchi M, Orita M, Ooshima K, Higashino H. Effects of Goreisan: a traditional Japanese Kampo medicine, on aquaporin 1, 2, 3, 4 and V2R mRNA expression in rat kidney and forebrain. J Med Sci. 2011;11(1):30-8. https://doi.org/10.3923/jms.2011.30.38
  19. Kim SY. Influence of Goryeosin infusion solution on the change of serum electrolytes in rats. Dajeon Univ 1990:1-38.
  20. Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417. https://doi.org/10.1016/j.jjcc.2019.05.003
  21. Shuji YAKUBO, Yuko KINOSHITA, Yasuyuki ARAKAWA, Masanao TAKA-HAsHI, Susumu KITANAKA. Clinical evaluation of Moku-boi-to(Mu-Fang-Yi-Tang):A Japanese and Chinese traditional medicine for heart failure. J.Trad.Med. 2002;19:159-163.
  22. Hirotaka Ezaki, Makoto Ayaori, Hiroki Sato, Yoshio Maeno, Masanori Taniwaki, Takayuki Miyake, Masami Sakurada. Effects of Mokuboito, a Japanese Kampo medicine, on symptoms in patients hospitalized for acute decompensated heart failure - A prospective randomized pilot study. Journal of Cardiology. 2019;74:412-417. https://doi.org/10.1016/j.jjcc.2019.05.003
  23. Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012;42:153-163. https://doi.org/10.1111/j.1365-2362.2011.02573.x